Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...
A deal that allows manufacturers to produce generic versions of lenacapavir has left out some Eastern European countries ...
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...